Cantor Fitzgerald Downgrades Amicus Therapeutics (FOLD) to Neutral

February 12, 2021 6:53 AM EST
Get Alerts FOLD Hot Sheet
Price: $9.85 -0.91%

Rating Summary:
    9 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 19 | New: 67
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Kristen Kluska downgraded Amicus Therapeutics (NASDAQ: FOLD) from Overweight to Neutral with a price target of $17.00 (from $30.00).

The analyst commented, "We are downgrading to Neutral from OW and lowering our PT to $17 from $30. Today (211),
Amicus reported highly anticipated Phase 3 PROPEL data for AT-GAA in Pompe disease, a rare lysosomal storage disorder. Bottom line, we got the call wrong, and Amicus narrowly missed the primary endpoint on statistically significant superiority over Lumizyme on change in six-minute walk distance (6MWD). That said, we believe AT-GAA was clearly efficacious, with clinically meaningful improvements observed across many important endpoints. We believe AT-GAA could still see an approval this year, but have less conviction on this potential. As a result of a lowered probability of success of approval (from 80% to 50%) and lowering our potential peak market penetration (from 48% to 20%) we are moving to the sidelines. We now model peak sales of ~$700M."

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $14.47 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Related Entities

Cantor Fitzgerald